Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
C6461001
Lung Cancer Phase III
- 13 weeks
- 1st site activated in Canada
C6461001
Lung Cancer Phase III
- 8.6 weeks
C6461001
Lung Cancer Phase III
- 10.6 weeks
C6461001
Lung Cancer Phase III
- 13.4 weeks
C6461001
Lung Cancer Phase III
- 19.8 weeks
C6461003
Colorectal cancer Phase III
- 10.6 weeks
C6461003
Colorectal cancer Phase III
- 10.4 weeks
CA266-0001
Non-small Cell Lung Cancer (NSCLC) Phase III
- 15 weeks
- 1st site activated in Canada
CA266-0003
Colorectal Cancer Phase II/III
- 9.6 weeks
- Canadian FPI
CA266-0003
Colorectal Cancer Phase II/III
- 7.8 weeks
CA266-0003
Colorectal Cancer Phase II/III
- 10.2 weeks
CA266-0003
Gastro-intestinal Cancer Phase II
- 9.6 weeks
- Canadian FPI
CA266-0003
Gastro-intestinal Cancer Phase II
- 7.8 weeks
CA266-0003
Gastro-intestinal Cancer Phase II
- 11.2 weeks
CDDY391B12201
Sjögren's disease Phase III
- 6.4 weeks
CEREN-3
ORL Phase III
- 10.4 weeks
- 1st site activated in Canada and Canadian FPI
CHJB647A12103
Chronic heart failure Phase Ib
- 10.6 weeks
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 8 weeks
- 2nd site activated worldwide and 1st site activated in Canada
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 9.6 weeks
CVAY736A22301
Sjögren's disease Phase III
- 9.2 weeks
- 1st site activated in Canada
D7700C00003 (CLEAR)
Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization Phase IIb
- 12.2 weeks
D8456C00001
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase IIb
- 12 weeks
- 3rd site activated worldwide
D8820C00003 (PRISM)
C. difficile Phase IIb
- 7 weeks
D8820C00003 (PRISM)
C. difficile Phase IIb
- 10.8 weeks